Cirrus Therapeutics
PrivateLast Round
Seed
Oct 2, 2025
Total Funding Raised
$11M
Momentum Score
50 /100
Company Overview
Cirrus Therapeutics is a biotechnology company developing gene and cell therapies for ocular immunology to treat conditions like age-related macular degeneration (AMD).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cirrus Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Cirrus Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Oct 2, 2025 |
Key People
Founding team and executive leadership
Cirrus Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SEEDS Capital | Seed |
| ClavystBio | Seed |
| Polaris Partners | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 17, 2026
Grew 120% QoQ from 5 to 11 employees.
- Oct 2, 2025
$11M round led by ClavystBio.
Cirrus Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Cirrus Therapeutics's valuation, stock price, and market status.
